©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jun 24, 2022; 13(6): 473-484
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.473
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.473
Circulating tumor DNA for diagnosis, prognosis and treatment of gastrointestinal malignancies
Patrick Kirchweger, Helwig Valentin Wundsam, Department of Surgery, Ordensklinikum Linz, Linz 4010, Austria
Patrick Kirchweger, Holger Rumpold, Gastrointestinal Cancer Center, Ordensklinikum Linz, Linz 4010, Austria
Patrick Kirchweger, Holger Rumpold, Medical Faculty, JKU University Linz, Linz 4040, Austria
Author contributions: Kirchweger P drafted the manuscript; Wundsam HV did extensive revisions; Rumpold H had the idea and co-drafted the manuscript and did revisions.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Holger Rumpold, MD, Associate Professor, Gastrointestinal Cancer Center, Ordensklinikum Linz, Barmherzige Schwestern, Seilerstätte 4, Linz 4010, Austria.
Received: March 1, 2021
Peer-review started: March 1, 2021
First decision: April 27, 2021
Revised: May 6, 2021
Accepted: May 26, 2022
Article in press: May 26, 2022
Published online: June 24, 2022
Processing time: 478 Days and 1.8 Hours
Peer-review started: March 1, 2021
First decision: April 27, 2021
Revised: May 6, 2021
Accepted: May 26, 2022
Article in press: May 26, 2022
Published online: June 24, 2022
Processing time: 478 Days and 1.8 Hours
Core Tip
Core Tip: This review provides an update on the state-of-the-art circulating tumor DNA detection via liquid biopsy for diagnosis, prognosis and treatment in gastrointestinal malignancies and presents the strengths and limitations of this innovative method.